Apoptotic markers in cancer.
暂无分享,去创建一个
[1] John Savill,et al. Corpse clearance defines the meaning of cell death , 2000, Nature.
[2] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[3] B. Vojtesek,et al. Release of cytokeratin‐18 and ‐19 fragments (TPS and CYFRA 21‐1) into the extracellular space during apoptosis , 2002, Journal of cellular biochemistry.
[4] G. Kramer,et al. Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 , 2004, Cancer Research.
[5] C. Rodríguez,et al. Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma , 2002, Cancer.
[6] S. Leung,et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.
[7] S. Linder,et al. Measurement of an apoptotic product in the sera of breast cancer patients. , 2003, European journal of cancer.
[8] Robert L Moritz,et al. Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.
[9] Ronit Vogt Sionov,et al. The cellular response to p53: the decision between life and death , 1999, Oncogene.
[10] S. Ho,et al. Monitoring Cytokeratin Fragment 19 (CYFRA 21-1) Serum Levels for Early Prediction of Recurrence of Adenocarcinoma and Squamous Cell Carcinoma in the Lung after Surgical Resection , 2002, Lung.
[11] E. Slee,et al. Serial killers: ordering caspase activation events in apoptosis , 1999, Cell Death and Differentiation.
[12] P. Nicotera,et al. Calcium and neuronal death. , 1998, Reviews of physiology, biochemistry and pharmacology.
[13] H. Mellstedt,et al. Increased serum levels of soluble Fas in progressive B‐CLL , 2001, European journal of haematology.
[14] F. Laval,et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. , 1995, Cancer letters.
[15] M. Ferdeghini,et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. , 2000, Cancer detection and prevention.
[16] A. Desmoulière,et al. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. , 1997, The international journal of biochemistry & cell biology.
[17] L. Pignataro,et al. Soluble Fas (sFas) and soluble Fas ligand (sFas‐L) balance in laryngeal carcinoma before and after surgical treatment , 2003, Journal of surgical oncology.
[18] Z. Darżynkiewicz,et al. Assays of cell viability: discrimination of cells dying by apoptosis. , 1994, Methods in cell biology.
[19] S. Ugurel,et al. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] B. Osborne,et al. Cell death in the third millennium , 2000, Cell Death and Differentiation.
[21] D. Ucker. Death and dying in the immune system. , 1997, Advances in pharmacology.
[22] Y. Chung,et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. , 1996, British Journal of Cancer.
[23] R. Govindan,et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] L. Zhang,et al. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. , 2001, Journal of hematotherapy & stem cell research.
[25] J F Kerr,et al. Shrinkage necrosis: A distinct mode of cellular death , 1971, The Journal of pathology.
[26] T. Majima,et al. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. , 2001, Oncology reports.
[27] U. Pastorino,et al. Detecting lung cancer in plasma with the use of multiple genetic markers , 2004, International journal of cancer.
[28] R. Stahel,et al. Circulating DNA: a new diagnostic gold mine? , 2002, Cancer treatment reviews.
[29] J. Pujol,et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. , 1996, American journal of respiratory and critical care medicine.
[30] M. Untch,et al. Nucleosomes in serum of patients with benign and malignant diseases , 2001, International journal of cancer.
[31] B. Persson,et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.
[32] A. Cossarizza,et al. Control of apoptosis by the cellular ATP level , 1996, FEBS letters.
[33] S. Leung,et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. , 1999, Cancer research.
[34] P. Nicotera,et al. Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.
[35] A. Wyllie,et al. Cell death: the significance of apoptosis. , 1980, International review of cytology.
[36] Qi-Lian Liang,et al. [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.
[37] P. Krammer,et al. CD95's deadly mission in the immune system , 2000, Nature.
[38] Jiazhen Le,et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma , 2003, The Journal of Laryngology & Otology.
[39] N. Niitsu,et al. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin’s lymphoma , 1999, Leukemia.
[40] Roger Y. Tsien,et al. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis , 2000, Nature Cell Biology.
[41] M. Toi,et al. Plasma nucleosome levels in node-negative breast cancer patients , 1999, Breast cancer.
[42] H. Kuwano,et al. Circulating soluble Fas ligand in patients with gastric carcinoma , 2000, Cancer.
[43] S. Yang,et al. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. , 2002, Anticancer research.
[44] J C Reed,et al. Mitochondria and apoptosis. , 1998, Science.
[45] M. Toi,et al. Circulating soluble Fas concentration in breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] Y. Kanda,et al. Lack of Correlation Between Clinical Characteristics and Serum Soluble Fas Ligand Levels in Patients with Multiple Myeloma , 2001, Leukemia & lymphoma.
[47] B. Shapiro,et al. Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.
[48] M. Takemura,et al. Serum‐soluble Fas level determines clinical symptoms and outcome of patients with aggressive non‐Hodgkin's lymphoma , 2000, American journal of hematology.
[49] M. Stroun,et al. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease , 2001, Leukemia.
[50] H Dienemann,et al. CYFRA 21‐1: A new marker in lung cancer , 1993, Cancer.
[51] David Sidransky,et al. Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.
[52] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[53] B. Zhivotovsky,et al. Apoptosis in human disease: a new skin for the old ceremony? , 1999, Biochemical and biophysical research communications.
[54] L. Ceriani,et al. Serum Cytokeratin Fragment 21.1 (CYFRA 21.1) as Tumour Marker for Breast Cancer: Comparison with Carbohydrate Antigen 15.3 (CA 15.3) and Carcinoembryonic Antigen (CEA) , 2002, Clinical chemistry and laboratory medicine.
[55] A. Heinecke,et al. CYFRA 21-1 serum analysis in patients with esophageal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] M. Monden,et al. [Tumor markers for colorectal cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.
[57] D. Bredesen,et al. An alternative, nonapoptotic form of programmed cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[58] S. Kaufmann,et al. Methods utilized in the study of apoptosis. , 1997, Advances in pharmacology.
[59] S. Leung,et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.
[60] K. Nasu,et al. Serum levels of cytokeratin 19 fragments in cervical cancer. , 1996, Gynecologic and obstetric investigation.
[61] J. Werner,et al. Follow-Up with Serum Cyfra 21-1 in Patients with Squamous Cell Carcinomas of the Head and Neck , 2002, Oncology.
[62] H. Dienemann,et al. Comparison of Cytokeratin Fragment 19 (CYFRA 21-1), Tissue Polypeptide Antigen (TPA) and Tissue Polypeptide Specific Antigen (TPS) as Tumour Markers in Lung Cancer , 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[63] B. Beghé,et al. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. , 1995, Quarterly Journal of Nuclear Medicine.
[64] E. Lane,et al. Lung Cancer-Associated Keratin 19 Fragments: Development and Biochemical Characterisation of the New Serum Assay Enzymun-Test® Cyfra 21–1 , 1994, The International journal of biological markers.
[65] Dean P. Jones,et al. Apoptosis: Cell death defined by caspase activation , 1999, Cell Death and Differentiation.
[66] Z. Darżynkiewicz,et al. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). , 1997, Cytometry.
[67] P. Stieber,et al. Apoptosis in serum of patients with solid tumours. , 1999, Anticancer research.
[68] L. Mariani,et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. , 2001, Cancer research.
[69] A. Wyllie,et al. Apoptosis. The role of the endonuclease. , 1990, The American journal of pathology.
[70] Y Chiba,et al. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] X. M. Sun,et al. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. , 1992, The Biochemical journal.
[72] G. Majno,et al. Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.
[73] C. Steinman,et al. Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome‐like structure and clearance , 1992, Clinical and experimental immunology.
[74] A. Maebo,et al. [Plasma DNA level as a tumor marker in primary lung cancer]. , 1990, Nihon Kyobu Shikkan Gakkai zasshi.
[75] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[76] L. Hefler,et al. Serum Soluble Fas Levels in Ovarian Cancer , 2000, Obstetrics and gynecology.
[77] V. Fadok,et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. , 1992, Journal of immunology.
[78] Tomomi Sato,et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level , 1998, Journal of Gastroenterology.
[79] S Niho,et al. [Tumor markers in lung cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.
[80] N. Nonomura,et al. Soluble Fas in serum from patients with renal cell carcinoma. , 2000, Urology.
[81] B. Stewart. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. , 1994, Journal of the National Cancer Institute.
[82] Jia-qing Li,et al. CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. , 2002, International journal of oncology.
[83] Luciana Dini,et al. Cell death: apoptosis versus necrosis (review). , 2002, International journal of oncology.
[84] S. Leung,et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. , 2000, Cancer research.
[85] Matthias Mann,et al. FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.
[86] H. Dienemann,et al. Comparison of Cyfra 21–1, Tpa and Tps in Lung Cancer, Urinary Bladder Cancer and Benign Diseases , 1994, The International journal of biological markers.
[87] Guido Kroemer,et al. The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.
[88] M. Páez de la Cadena,et al. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. , 2003, Oncology reports.
[89] G. Prindull. Apoptosis in the embryo and tumorigenesis. , 1995, European journal of cancer.
[90] J. Pujol,et al. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. , 1998, Cancer detection and prevention.
[91] M. Leist,et al. In vivo and in vitro evidence for extracellular caspase activity released from apoptotic cells. , 2001, Biochemical and biophysical research communications.
[92] T. Takano,et al. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[93] F. O. Fackelmayer,et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.
[94] J. Kerr,et al. Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. , 1992, International journal of radiation biology.
[95] P. Krammer. CD95(APO-1/Fas)-mediated apoptosis: live and let die. , 1999, Advances in immunology.
[96] A. Takise,et al. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. , 1997, Oncology.
[97] A. Dueñas-González,et al. Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients , 2003, International journal of cancer.
[98] P. Clarke,et al. Nineteenth century research on naturally occurring cell death and related phenomena , 1996, Anatomy and Embryology.
[99] A. Glücksmann. CELL DEATHS IN NORMAL VERTEBRATE ONTOGENY , 1951 .
[100] H. Mulcahy,et al. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: Time for large‐scale clinical studies? , 2003, International journal of cancer.
[101] C. Winterford,et al. Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.
[102] Michael Thomas,et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. , 2002, Lung cancer.
[103] J. Herman,et al. Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.
[104] D. Nicholson,et al. Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.
[105] J. Weinberg,et al. Apoptosis: definition, mechanisms, and relevance to disease. , 1999, The American journal of medicine.
[106] P. Schär,et al. Spontaneous DNA Damage, Genome Instability, and Cancer—When DNA Replication Escapes Control , 2001, Cell.
[107] M. Toi,et al. Clinical significance of plasma nucleosome levels in cancer patients. , 2001, International journal of oncology.
[108] K. Feldmann,et al. Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[109] K. Braithwaite,et al. Multi-step evolution of lung cancer. , 1999, Seminars in cancer biology.
[110] Lakshmi Goyal. Cell Death Inhibition Keeping Caspases in Check , 2001, Cell.
[111] M. Andreeff,et al. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. , 1997, Leukemia & lymphoma.
[112] V. Lipkin,et al. Soluble Fas Antigen in the Serum of Patients with Colon Cancer , 2001, Bulletin of Experimental Biology and Medicine.
[113] J L Pujol,et al. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. , 2001, Lung cancer.
[114] P. Nicotera,et al. Execution of Apoptosis: Converging or Diverging Pathways? , 1999, Biological chemistry.
[115] V. Dixit,et al. Death receptors: signaling and modulation. , 1998, Science.
[116] T. Mak,et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death , 2001, Nature.
[117] P. Krammer,et al. Molecular Mechanisms of Death‐Receptor‐Mediated Apoptosis , 2001, Chembiochem : a European journal of chemical biology.
[118] Mariano Provencio,et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[119] S. Emr,et al. Autophagy as a regulated pathway of cellular degradation. , 2000, Science.
[120] B. McManus,et al. Apoptosis: molecular aspects of cell death and disease. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[121] H. Nakahama,et al. CYFRA 21‐1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients , 1998, Respirology.
[122] John Calvin Reed,et al. Endogenous Inhibitors of Caspases , 1999, Journal of Clinical Immunology.
[123] S. Sheen-Chen,et al. Circulating Soluble Fas in Patients with Breast Cancer , 2003, World Journal of Surgery.
[124] B. Zhivotovsky,et al. ‘Centennial’ Nobel Conference on apoptosis and human disease , 2002, Cell Death and Differentiation.
[125] S. Nagata,et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.
[126] John Calvin Reed. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. , 1997, Advances in pharmacology.
[127] R. Weiss,et al. Urine detection of survivin and diagnosis of bladder cancer. , 2001, JAMA.
[128] S. Sun,et al. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. , 2000, American journal of clinical oncology.
[129] Y. Tomita,et al. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients , 1999, British Journal of Cancer.
[130] K. Sasajima,et al. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus , 1999, Medical oncology.
[131] Marcel Leist,et al. Four deaths and a funeral: from caspases to alternative mechanisms , 2001, Nature Reviews Molecular Cell Biology.
[132] R. Molina,et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[133] N. Viñolas,et al. Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis , 2003, Tumor Biology.
[134] Y. Mizutani,et al. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. , 2002, Cancer biotherapy & radiopharmaceuticals.
[135] H. D. de Bruijn,et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. , 2002, International journal of radiation oncology, biology, physics.
[136] U. Pastorino,et al. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer , 2003 .
[137] C. Hess,et al. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. , 2002, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[138] R. Neumann,et al. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. , 2003, Oncology reports.
[139] C. Kao,et al. Comparison of Cyfra 21–1 and Squamous Cell Carcinoma Antigen in Detecting Nasopharyngeal Carcinoma , 2001, Annals of Otology, Rhinology and Laryngology.
[140] S. Leung,et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. , 2003, Cancer research.
[141] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[142] A. Hart,et al. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. , 1994, Gynecologic oncology.
[143] A. Hart,et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. , 1999, Lung cancer.
[144] R. Hodes,et al. What Does Cell Death Have To Do with Aging? , 1997, Journal of the American Geriatrics Society.
[145] P. Stieber,et al. Circulating Nucleosomes in Serum , 2001, Annals of the New York Academy of Sciences.
[146] P. Lamy,et al. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. , 2003, Lung cancer.
[147] M. Jäättelä,et al. Escaping cell death: survival proteins in cancer. , 1999, Experimental cell research.
[148] M. Untch,et al. Nucleosomes in Serum as a Marker for Cell Death , 2001, Clinical chemistry and laboratory medicine.
[149] P Stieber,et al. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. , 1994, Anticancer research.
[150] B. Shapiro,et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.
[151] P. Nicotera,et al. Intracellular ATP, a switch in the decision between apoptosis and necrosis. , 1998, Toxicology letters.
[152] M. Hengartner. Apoptosis Corralling the Corpses , 2001, Cell.
[153] D. Ferrigno,et al. Lung tumor markers of cytokeratin origin: an overview. , 2001, Lung cancer.
[154] John Calvin Reed. Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] S. Nagata,et al. Apoptosis by Death Factor , 1997, Cell.
[156] E. Altieri,et al. Cyfra 21-1 marker in carcinoma of the cervix. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[157] P. Johnson,et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[158] J. Hickman,et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. , 1993, The EMBO journal.
[159] M. Lutter,et al. Biochemical pathways of caspase activation during apoptosis. , 1999, Annual review of cell and developmental biology.
[160] H. Dienemann,et al. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. , 2003, Anticancer research.
[161] P. Williamson,et al. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes , 1995, The Journal of experimental medicine.
[162] T. Uenishi,et al. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer , 2003, British Journal of Cancer.
[163] Y. Mizutani,et al. Significance of serum soluble fas ligand in patients with bladder carcinoma , 2001, Cancer.
[164] Rachel L. Allen,et al. Defying death after DNA damage , 2000, Nature.
[165] D. Khayat,et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma , 2000, Melanoma research.
[166] J. Daurès,et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.
[167] V. Vasioukhin,et al. The Origin and Mechanism of Circulating DNA , 2000, Annals of the New York Academy of Sciences.
[168] Apoptosis regulators and their role in tumorigenesis. , 2001 .
[169] Xiaodong Wang,et al. Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.
[170] L. Ceriani,et al. Immunoassay of Neuron-Specific Enolase (Nse) and Serum Fragments of Cytokeratin 19 (Cyfra 21.1) as Tumor Markers in Small Cell Lung Cancer: Clinical Evaluation and Biological Hypothesis , 1997, The International journal of biological markers.
[171] S. Umansky,et al. Circulating Nucleic Acids and Apoptosis , 2001, Annals of the New York Academy of Sciences.
[172] T. Cotter,et al. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. , 1990, Anticancer research.
[173] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.